Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 138 entries
Sorted by: Best Match Show Resources per page
Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi.

Public health action

Kanyerere H, Mganga A, Harries AD, Tayler-Smith K, Jahn A, Chimbwandira FM, Mpunga J.
PMID: 26399210
Public Health Action. 2014 Jun 21;4(2):113-5. doi: 10.5588/pha.14.0018.

From 2000 to 2012, Malawi scaled up antiretroviral therapy (ART) from

Cite
Kanyerere H, Mganga A, Harries AD, et al. Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi. Public Health Action. 2014;4(2):113-5doi: 10.5588/pha.14.0018.
Kanyerere, H., Mganga, A., Harries, A. D., Tayler-Smith, K., Jahn, A., Chimbwandira, F. M., & Mpunga, J. (2014). Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi. Public health action, 4(2), 113-5. https://doi.org/10.5588/pha.14.0018
Kanyerere, H, et al. "Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi." Public health action vol. 4,2 (2014): 113-5. doi: https://doi.org/10.5588/pha.14.0018
Kanyerere H, Mganga A, Harries AD, Tayler-Smith K, Jahn A, Chimbwandira FM, Mpunga J. Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi. Public Health Action. 2014 Jun 21;4(2):113-5. doi: 10.5588/pha.14.0018. PMID: 26399210; PMCID: PMC4539031.
Copy Download .nbib Format: NLM
Ethylene Glycol Toxicity: Chemistry, Pathogenesis, and Imaging.

Radiology case reports

Moore MM, Kanekar SG, Dhamija R.
PMID: 27303504
Radiol Case Rep. 2015 Nov 06;3(1):122. doi: 10.2484/rcr.v3i1.122. eCollection 2008.

The ingestion of ethylene glycol results in toxicity with characteristic chemical, pathological, and imaging findings. In the case presented, magnetic resonance imaging demonstrated bilateral symmetric hyperintensity within the basal ganglia, thalami, and brainstem. Ethylene glycol toxicity also resulted in...

Cite
Moore MM, Kanekar SG, Dhamija R. Ethylene Glycol Toxicity: Chemistry, Pathogenesis, and Imaging. Radiol Case Rep. 2015;3(1):122doi: 10.2484/rcr.v3i1.122.
Moore, M. M., Kanekar, S. G., & Dhamija, R. (2008). Ethylene Glycol Toxicity: Chemistry, Pathogenesis, and Imaging. Radiology case reports, 3(1), 122. https://doi.org/10.2484/rcr.v3i1.122
Moore, Michael M, et al. "Ethylene Glycol Toxicity: Chemistry, Pathogenesis, and Imaging." Radiology case reports vol. 3,1 (2008): 122. doi: https://doi.org/10.2484/rcr.v3i1.122
Moore MM, Kanekar SG, Dhamija R. Ethylene Glycol Toxicity: Chemistry, Pathogenesis, and Imaging. Radiol Case Rep. 2015 Nov 06;3(1):122. doi: 10.2484/rcr.v3i1.122. eCollection 2008. PMID: 27303504; PMCID: PMC4896169.
Copy Download .nbib Format: NLM
Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality.

Transplantation direct

Bassetti M, Peghin M, Carnelutti A, Righi E, Merelli M, Ansaldi F, Trucchi C, Alicino C, Sartor A, Wauters J, Lagrou K, Tascini C, Menichetti F, Mesini A, De Rosa FG, Lagunes L, Rello J, Colombo AL, Vena A, Munoz P, Tumbarello M, Sganga G, Martin-Loeches I, Viscoli C.
PMID: 28573191
Transplant Direct. 2017 Apr 18;3(5):e156. doi: 10.1097/TXD.0000000000000673. eCollection 2017 May.

BACKGROUND: Invasive fungal infections remain a leading cause of morbidity and mortality among liver transplant recipients (LTRs). In this patient population, invasive Candida infections (ICIs) account for the large majority of cases. To date, only small studies and case-series...

Cite
Bassetti M, Peghin M, Carnelutti A, et al. Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplant Direct. 2017;3(5):e156doi: 10.1097/TXD.0000000000000673.
Bassetti, M., Peghin, M., Carnelutti, A., Righi, E., Merelli, M., Ansaldi, F., Trucchi, C., Alicino, C., Sartor, A., Wauters, J., Lagrou, K., Tascini, C., Menichetti, F., Mesini, A., De Rosa, F. G., Lagunes, L., Rello, J., Colombo, A. L., Vena, A., Munoz, P., Tumbarello, M., Sganga, G., Martin-Loeches, I., & Viscoli, C. (2017). Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation direct, 3(5), e156. https://doi.org/10.1097/TXD.0000000000000673
Bassetti, Matteo, et al. "Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality." Transplantation direct vol. 3,5 (2017): e156. doi: https://doi.org/10.1097/TXD.0000000000000673
Bassetti M, Peghin M, Carnelutti A, Righi E, Merelli M, Ansaldi F, Trucchi C, Alicino C, Sartor A, Wauters J, Lagrou K, Tascini C, Menichetti F, Mesini A, De Rosa FG, Lagunes L, Rello J, Colombo AL, Vena A, Munoz P, Tumbarello M, Sganga G, Martin-Loeches I, Viscoli C. Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplant Direct. 2017 Apr 18;3(5):e156. doi: 10.1097/TXD.0000000000000673. eCollection 2017 May. PMID: 28573191; PMCID: PMC5441987.
Copy Download .nbib Format: NLM
Case 1: An 11-year-old girl with bilateral hip and groin pain.

Paediatrics & child health

Levin H, Lim R, Sangha G.
PMID: 26744564
Paediatr Child Health. 2015 Nov-Dec;20(8):e48-9. doi: 10.1093/pch/20.8.e48.

No abstract available.

Cite
Levin H, Lim R, Sangha G. Case 1: An 11-year-old girl with bilateral hip and groin pain. Paediatr Child Health. 2015;20(8):e48-9doi: 10.1093/pch/20.8.e48.
Levin, H., Lim, R., & Sangha, G. (2015). Case 1: An 11-year-old girl with bilateral hip and groin pain. Paediatrics & child health, 20(8), e48-9. https://doi.org/10.1093/pch/20.8.e48
Levin, Helen, et al. "Case 1: An 11-year-old girl with bilateral hip and groin pain." Paediatrics & child health vol. 20,8 (2015): e48-9. doi: https://doi.org/10.1093/pch/20.8.e48
Levin H, Lim R, Sangha G. Case 1: An 11-year-old girl with bilateral hip and groin pain. Paediatr Child Health. 2015 Nov-Dec;20(8):e48-9. doi: 10.1093/pch/20.8.e48. PMID: 26744564; PMCID: PMC4699535.
Copy Download .nbib Format: NLM
Novel drug targets for idiopathic pulmonary fibrosis.

Expert review of respiratory medicine

Sgalla G, Cocconcelli E, Tonelli R, Richeldi L.
PMID: 26854382
Expert Rev Respir Med. 2016 Apr;10(4):393-405. doi: 10.1586/17476348.2016.1152186. Epub 2016 Feb 26.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal lung disorder of unknown cause with a highly variable and unpredictable clinical course. The advances made in deciphering IPF pathobiology over the last decades have led to the approval of two...

Cite
Sgalla G, Cocconcelli E, Tonelli R, et al. Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016;10(4):393-405doi: 10.1586/17476348.2016.1152186.
Sgalla, G., Cocconcelli, E., Tonelli, R., & Richeldi, L. (2016). Novel drug targets for idiopathic pulmonary fibrosis. Expert review of respiratory medicine, 10(4), 393-405. https://doi.org/10.1586/17476348.2016.1152186
Sgalla, Giacomo, et al. "Novel drug targets for idiopathic pulmonary fibrosis." Expert review of respiratory medicine vol. 10,4 (2016): 393-405. doi: https://doi.org/10.1586/17476348.2016.1152186
Sgalla G, Cocconcelli E, Tonelli R, Richeldi L. Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016 Apr;10(4):393-405. doi: 10.1586/17476348.2016.1152186. Epub 2016 Feb 26. PMID: 26854382.
Copy Download .nbib Format: NLM
Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?.

Hepatology (Baltimore, Md.)

Scanga A, Kowdley K.
PMID: 19115217
Hepatology. 2009 Jan;49(1):332-4. doi: 10.1002/hep.22756.

No abstract available.

Cite
Scanga A, Kowdley K. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?. Hepatology. 2009;49(1):332-4doi: 10.1002/hep.22756.
Scanga, A., & Kowdley, K. (2009). Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?. Hepatology (Baltimore, Md.), 49(1), 332-4. https://doi.org/10.1002/hep.22756
Scanga, Andrew, and Kowdley, Kris. "Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?." Hepatology (Baltimore, Md.) vol. 49,1 (2009): 332-4. doi: https://doi.org/10.1002/hep.22756
Scanga A, Kowdley K. Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?. Hepatology. 2009 Jan;49(1):332-4. doi: 10.1002/hep.22756. PMID: 19115217.
Copy Download .nbib Format: NLM
Raman study of CuO single crystals.

Physical review. B, Condensed matter

Bourne LC, Chaminade JP, Goldstein HF, Kim Ds, Nganga L, Yu PY.
PMID: 9992981
Phys Rev B Condens Matter. 1990 Apr 01;41(10):7192-7194. doi: 10.1103/physrevb.41.7192.

No abstract available.

Cite
Bourne LC, Chaminade JP, Goldstein HF, et al. Raman study of CuO single crystals. Phys Rev B Condens Matter. 1990;41(10):7192-7194doi: 10.1103/physrevb.41.7192.
Bourne, L. C., Chaminade, J. P., Goldstein, H. F., Kim, D. s., Nganga, L., & Yu, P. Y. (1990). Raman study of CuO single crystals. Physical review. B, Condensed matter, 41(10), 7192-7194. https://doi.org/10.1103/physrevb.41.7192
Bourne, et al. "Raman study of CuO single crystals." Physical review. B, Condensed matter vol. 41,10 (1990): 7192-7194. doi: https://doi.org/10.1103/physrevb.41.7192
Bourne LC, Chaminade JP, Goldstein HF, Kim Ds, Nganga L, Yu PY. Raman study of CuO single crystals. Phys Rev B Condens Matter. 1990 Apr 01;41(10):7192-7194. doi: 10.1103/physrevb.41.7192. PMID: 9992981.
Copy Download .nbib Format: NLM
Randomized Trials of Nasal Patency and Dermal Tolerability With External Nasal Dilators in Healthy Volunteers.

Allergy & rhinology (Providence, R.I.)

Ward J, Ciesla R, Becker W, Shanga GM.
PMID: 30305980
Allergy Rhinol (Providence). 2018 Oct 05;9:2152656718796740. doi: 10.1177/2152656718796740. eCollection 2018.

BACKGROUND: External nasal dilator strips are used as nonpharmacological therapy to reduce snoring and daytime sleepiness. In a product improvement initiative, a marketed strip (BRNS) and 2 prototype nasal strips were evaluated.OBJECTIVE: To compare the nasal patency and multiple-use...

Cite
Ward J, Ciesla R, Becker W, et al. Randomized Trials of Nasal Patency and Dermal Tolerability With External Nasal Dilators in Healthy Volunteers. Allergy Rhinol (Providence). 2018;9:2152656718796740doi: 10.1177/2152656718796740.
Ward, J., Ciesla, R., Becker, W., & Shanga, G. M. (2018). Randomized Trials of Nasal Patency and Dermal Tolerability With External Nasal Dilators in Healthy Volunteers. Allergy & rhinology (Providence, R.I.), 92152656718796740. https://doi.org/10.1177/2152656718796740
Ward, John, et al. "Randomized Trials of Nasal Patency and Dermal Tolerability With External Nasal Dilators in Healthy Volunteers." Allergy & rhinology (Providence, R.I.) vol. 9 (2018): 2152656718796740. doi: https://doi.org/10.1177/2152656718796740
Ward J, Ciesla R, Becker W, Shanga GM. Randomized Trials of Nasal Patency and Dermal Tolerability With External Nasal Dilators in Healthy Volunteers. Allergy Rhinol (Providence). 2018 Oct 05;9:2152656718796740. doi: 10.1177/2152656718796740. eCollection 2018. PMID: 30305980; PMCID: PMC6174651.
Copy Download .nbib Format: NLM
Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya.

Wellcome open research

Njue M, Njuguna P, Kapulu MC, Sanga G, Bejon P, Marsh V, Molyneux S, Kamuya D.
PMID: 29806038
Wellcome Open Res. 2018 Apr 11;3:39. doi: 10.12688/wellcomeopenres.14439.1. eCollection 2018.

No abstract available.

Cite
Njue M, Njuguna P, Kapulu MC, et al. Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. Wellcome Open Res. 2018;3:39doi: 10.12688/wellcomeopenres.14439.1.
Njue, M., Njuguna, P., Kapulu, M. C., Sanga, G., Bejon, P., Marsh, V., Molyneux, S., & Kamuya, D. (2018). Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. Wellcome open research, 339. https://doi.org/10.12688/wellcomeopenres.14439.1
Njue, Maureen, et al. "Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya." Wellcome open research vol. 3 (2018): 39. doi: https://doi.org/10.12688/wellcomeopenres.14439.1
Njue M, Njuguna P, Kapulu MC, Sanga G, Bejon P, Marsh V, Molyneux S, Kamuya D. Ethical considerations in Controlled Human Malaria Infection studies in low resource settings: Experiences and perceptions of study participants in a malaria Challenge study in Kenya. Wellcome Open Res. 2018 Apr 11;3:39. doi: 10.12688/wellcomeopenres.14439.1. eCollection 2018. PMID: 29806038; PMCID: PMC5954342.
Copy Download .nbib Format: NLM
Effects of nasal dilator strips on subjective measures of sleep in subjects with chronic nocturnal nasal congestion: a randomized, placebo-controlled trial.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology

Schenkel EJ, Ciesla R, Shanga GM.
PMID: 30154874
Allergy Asthma Clin Immunol. 2018 Aug 27;14:34. doi: 10.1186/s13223-018-0258-5. eCollection 2018.

BACKGROUND: This exploratory study investigated effects of a new asymmetric butterfly-shaped prototype nasal dilator strip and the currently marketed clear Breathe Right Nasal Strip (BRNS) on subjective measures of nasal congestion and sleep quality.METHODS: In this randomized, double-blind study,...

Cite
Schenkel EJ, Ciesla R, Shanga GM. Effects of nasal dilator strips on subjective measures of sleep in subjects with chronic nocturnal nasal congestion: a randomized, placebo-controlled trial. Allergy Asthma Clin Immunol. 2018;14:34doi: 10.1186/s13223-018-0258-5.
Schenkel, E. J., Ciesla, R., & Shanga, G. M. (2018). Effects of nasal dilator strips on subjective measures of sleep in subjects with chronic nocturnal nasal congestion: a randomized, placebo-controlled trial. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 1434. https://doi.org/10.1186/s13223-018-0258-5
Schenkel, Eric J, et al. "Effects of nasal dilator strips on subjective measures of sleep in subjects with chronic nocturnal nasal congestion: a randomized, placebo-controlled trial." Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology vol. 14 (2018): 34. doi: https://doi.org/10.1186/s13223-018-0258-5
Schenkel EJ, Ciesla R, Shanga GM. Effects of nasal dilator strips on subjective measures of sleep in subjects with chronic nocturnal nasal congestion: a randomized, placebo-controlled trial. Allergy Asthma Clin Immunol. 2018 Aug 27;14:34. doi: 10.1186/s13223-018-0258-5. eCollection 2018. PMID: 30154874; PMCID: PMC6109978.
Copy Download .nbib Format: NLM
Antimycoplasmal Activities of Compounds from .

Frontiers in pharmacology

Kama-Kama F, Omosa LK, Nganga J, Maina N, Osanjo G, Yaouba S, Ilias M, Midiwo J, Naessens J.
PMID: 29311927
Front Pharmacol. 2017 Dec 21;8:920. doi: 10.3389/fphar.2017.00920. eCollection 2017.

Infections caused by

Cite
Kama-Kama F, Omosa LK, Nganga J, et al. Antimycoplasmal Activities of Compounds from . Front Pharmacol. 2017;8:920doi: 10.3389/fphar.2017.00920.
Kama-Kama, F., Omosa, L. K., Nganga, J., Maina, N., Osanjo, G., Yaouba, S., Ilias, M., Midiwo, J., & Naessens, J. (2017). Antimycoplasmal Activities of Compounds from . Frontiers in pharmacology, 8920. https://doi.org/10.3389/fphar.2017.00920
Kama-Kama, Francisca, et al. "Antimycoplasmal Activities of Compounds from ." Frontiers in pharmacology vol. 8 (2017): 920. doi: https://doi.org/10.3389/fphar.2017.00920
Kama-Kama F, Omosa LK, Nganga J, Maina N, Osanjo G, Yaouba S, Ilias M, Midiwo J, Naessens J. Antimycoplasmal Activities of Compounds from . Front Pharmacol. 2017 Dec 21;8:920. doi: 10.3389/fphar.2017.00920. eCollection 2017. PMID: 29311927; PMCID: PMC5742823.
Copy Download .nbib Format: NLM
Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.

PloS one

Djebbari F, Rampotas A, Panitsas F, Lim WY, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Eyre TA, Moore S, Kothari J, Ramasamy K.
PMID: 35015781
PLoS One. 2022 Jan 11;17(1):e0262388. doi: 10.1371/journal.pone.0262388. eCollection 2022.

The management of myeloma in the elderly is shifting its focus towards reducing the risk of under-treating fit patients and the risk of over-treating frail patients. Frailty assessment is required in this patient group in order to individualise treatment...

Cite
Djebbari F, Rampotas A, Panitsas F, et al. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PLoS One. 2022;17(1):e0262388doi: 10.1371/journal.pone.0262388.
Djebbari, F., Rampotas, A., Panitsas, F., Lim, W. Y., Lees, C., Tsagkaraki, I., Gomes, A. R., Prideaux, S., Chen, L., Prodger, C., Khera, A., Gray, N., Ellis, L., Sangha, G., Eyre, T. A., Moore, S., Kothari, J., & Ramasamy, K. (2022). Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PloS one, 17(1), e0262388. https://doi.org/10.1371/journal.pone.0262388
Djebbari, Faouzi, et al. "Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients." PloS one vol. 17,1 (2022): e0262388. doi: https://doi.org/10.1371/journal.pone.0262388
Djebbari F, Rampotas A, Panitsas F, Lim WY, Lees C, Tsagkaraki I, Gomes AR, Prideaux S, Chen L, Prodger C, Khera A, Gray N, Ellis L, Sangha G, Eyre TA, Moore S, Kothari J, Ramasamy K. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients. PLoS One. 2022 Jan 11;17(1):e0262388. doi: 10.1371/journal.pone.0262388. eCollection 2022. PMID: 35015781.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 138 entries